HOLLISTON, Mass., Nov. 10, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB:BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that it will release Q3 2022 financial results on November 14, 2022 and host a conference call and webcast on November 15, 2022 at 9:00 AM ET to discuss financial results and business updates for the third-quarter 2022.
Read more at prnewswire.comBiostage Schedules Conference Call and Webcast for Q3 2022 Results
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
/Bundle%20of%20optical%20fiber%20cables%20with%20lights%20by%20volff%20via%20Adobe%20Stock.jpeg)
